J&J のワクチンの効果と安全性報告論文
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Apr 2021 – Sep 2025Where it's discussed
-
X / Twitter282 posts
-
News214 articles
-
Blogs15 articles
-
Facebook10 posts
-
YouTube4 videos
-
Reddit2 posts
AI synopsis
What people are saying
Several posts prominently reference the publication's findings, with discussions mentioning the 66.9% efficacy against moderate to severe COVID-19 cases and noting the vaccine's performance against variants. The tone varies, with some using emphatic language like 'must consider' and 'game changer,' while others challenge skeptics, promoting terms like 'long-term safety' and 'strong efficacy,' indicating a robust exchange of opinions and a collective sense of importance regarding the vaccination topic.
The majority of discussions reflect a generally supportive view towards the findings of the publication.
The discussions show a high level of curiosity, with many users actively referencing the study's data and linking to further research.
While many discussions consist of fast-paced exchanges, a number contain detailed references to clinical trials and their results, indicating a moderate depth of engagement.
A strong sentiment exists about the significance of the vaccine findings, with many users believing that the vaccine has broad implications for public health.
Abstract in brief
- The Ad26.COV2.S vaccine is a single-dose shot designed to protect against Covid-19 by using a harmless version of a virus to deliver genetic material that helps the body recognize and fight the Covid-19 virus.
- In a large clinical trial with nearly 39,000 participants, those who received the Ad26.COV2.S vaccine showed a 66.9% efficacy in preventing moderate to severe Covid-19 cases after 14 days compared to the placebo group.
- The vaccine also proved effective against variations of the virus, particularly in South Africa, showing efficacy rates of 52.0% to 73.1%, while side effects were generally mild to moderate and temporary.
Top posts
Most liked on X and BlueskyClinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vaccine, works well against hospitalization and death ! 'Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | https://t.co/N9TWQWOUP6
J&Jのウイルスベクターワクチン 19630人VS19691人のRCT 1回接種 14日以上で 中等症〜重症 66.9%減 重症〜重篤 76.7%減 28日以上で 中等症〜重症 66.1%減 重症〜重篤 85.4%減 https://t.co/DYQ0TVF0EA
Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZeneca: https://t.co/7uSm3LKsez Novavax: https://t.co/mOrR0EKvpJ
@robbswallace Do you wonder why I posted peer-reviewed scientific papers and you posted a popular news article and a link that didn't work? Also, oops you're wrong about the vaccine too womp womp https://t.co/wfciWnZtXO
@CorrNotCausa @Farmaenfurecida @Ari_Arifu2 Bueno, veamos cuanto tardas en mover la portería. Seguridad y eficacia de una vacuna de vector viral. No son modelos, ni casos anecdóticos, ni opiniones. Es un ensayo clínico aleatorizado y doble ciego (con su correspondiente grupo control). https://t.co/kLKQP63Sjf
All mentions
Szurkálódjunk!: COVID-vakcinák - csak egyszerűen
Healthcare Workers' Concerns Over Mandatory Vaccination
Depuis plusieurs mois, des agents hospitaliers doutent face au vaccin. Cette vidéo explore les raisons soulevées concernant l'obligation vaccinale, tout en discutant des résultats préliminaires de la sécurité des…
Doug Cameron's Testimony to Expert Panel on COVID-19 Vaccine Injuries
COVID-19 Virus Transmission Study in Vaccinated vs. Unvaccinated Individuals
We join Dr. Ndema Habib to discuss a study on COVID-19 infections within the community among vaccinated and unvaccinated individuals in the UK. The research focuses on the dynamics of SARS-CoV-2 transmission, shedding…
@davostwatos @rowleythelegend @LBC @lewis_goodall COVID vaccines went through large-scale Phase 3 trials before rollout.
34/ References 1. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021;384:2187–201. https://t.co/KaJIHyo9pL.
@fcOpaleye @yuya1209369 その6: Sadoff, J., et al. (2021). "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine Against Covid-19." New England Journal of Medicine, 384(23), 2187-2201. 続く
@Fides_Veritas @cremieuxrecueil J&J had human clinical trials as well. https://t.co/6yutxx8jUU
@lyaelsmith @Censored4sure @DrNeilStone https://t.co/A63WInEcJE https://t.co/OVteyEDuV9 https://t.co/DcAvt4bRk0 https://t.co/UGuV90xYdY https://t.co/kHADWXPGCx https://t.co/Mt6Ep97QA9 https://t.co/MgwBHrVS6a https://t.co/FTWa1cBO62
@Jean__Fisch @Takeastepback16 There is only smoke if he has some proof that the clinical phases 1 to 3 were not done. Meaning that the following research has not been done: https://t.co/BMyzkOg8H7 So where is the smoke?
@TeetBeeZoon @ScottAnd67 Have you ever tried to make your own research? No? I'm not surprised. You're wrong on so many levels. https://t.co/KNbQkA0eij https://t.co/rbHTpPLNm7
RT @Leo1401j: Full phase 3 study: https://t.co/xze23otYG8
RT @Leo1401j: Full phase 3 study: https://t.co/xze23otYG8
Full phase 3 study: https://t.co/xze23otYG8
@hosokawasfriend @ishikawa_poli @SatorismT あるよー。 ENSEMBLE試験→J&J社の新型コロナベクターワクチン https://t.co/44RPedkC0I
@steve_nardone @DrNeilStone Sure, I've got fucking loads of them https://t.co/NrvJurTpps https://t.co/CcfUPHwKar https://t.co/paBJRSmiJ1 https://t.co/GpN0TZtjJS https://t.co/4olVOfum2O
@Logos_siochain @meokater @littlewisehen @grok 37. Sadoff et al., 2021 https://t.co/8r7LFPjzcj 38. Shrotri et al., 2021 https://t.co/B8MzNXWsmw 39. Skowronski et al., 2022 https://t.co/kemCoeJJ28 40. Tan et al., 2023 https://t.co/Mbh7xg6YMf
@coach28373 @AnnieForTruth What are you talking about? There's heaps of double-blind placebo vaccine studies. https://t.co/WJSW1IUe4u https://t.co/FCU7xC2qph https://t.co/jOPsPbLhMI (etc, etc, etc)
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
@dvinepunishment @leopoldolfmv @BiazitaGomes @mahpenna https://t.co/wUjJH2MszB
@GoodbackC18416 @simonmaechling Here's the next two. AstraZeneca-Oxford (ChAdOx1 nCoV-19) Vaccine: Published in The Lancet
@statonomic @JBTC1971 @DrSusanOliver1 @TiredofNoticing Go eat a dick and get educated, ignorant idiot. You’re welcome. https://t.co/TxK8MSf0cz https://t.co/0LWs8DQFhU
@PeterSticks_ @AlastairMcA30 @meezike https://t.co/OMvb0A9uEt … like wtf are you talking about ?
@Bmilhouse @DocDeezWhat @JReinerMD @whstancil https://t.co/D1R78kGOyH
@biifiib Sono bravo e ti metto anche il Paper originale… Si fa sempre in tempo ad imparare qualcosa https://t.co/8ehLQKWe3g
@alaskamoosepics @RetsefL Those results came in a month before: https://t.co/vs48C7D0q6
@marco_borrano Non è vero che credi agli RCT, credi solo a quelli che ti fanno comodo Ecco altri 5 RCT, coglione 1. https://t.co/a9lv8vQrbF 2. https://t.co/LGLJxvqCX4 3. https://t.co/sMtLyJo2Pd 4. https://t.co/kE29967XrY 5. https://t.co/cF5bs20GxP
@robinhoodlego @RogerZenAF i would also like to thank you for listing sources, but here are a couple of mine 1. [NEJM Study on Pfizer-BioNTech Vaccine](https://t.co/oY3bIF8QoD) 2. [NEJM Study on Moderna Vaccine](https://t.co/pL1yywmtyN) 3. [NEJM Study on Johnson & Johnson Vaccine](https://t.co/EIOegzcdrb)
@ivan_skava65522 Astrazeneca: Saline https://t.co/gPouBRaCEQ J&J: Saline https://t.co/in3onPzhud Pfizer: Saline https://t.co/Tgeu7tbdqv Moderna: Saline https://t.co/82J2sXTJVK Source: clinical trial studies for each.
@PickEmLegend @market_memetics @Charlie81789387 @Yaboot710 @Scary7Dr @Pouldeau61 @TonyBaduy @lavalmxhr @FitnessApple106 @EyeOfTheMagi @zee_parody @VaxPaparazzi @AndyJLumm @HossmanOfficial @Mike6150817700 @TruthHurt001260 @Cloud7Connected @karleastlondon @dirk_fasshauer @KilldareDoc3088 @JimeeLiberty @TruthHurts02160 @Mike61508177700 @JKelleyK @mcfunny @richykirsh @jilel76 @J91U17 @nobodyknows1017 @Wackenhut375 @nyob7714 @BurgerLab12 @swords_mr @bjurrows @epigeneticallyj @saltbeefsandwch @Veeteejay1 @PlatoonOps @charlespinion @SolleyButler @Agent2Dark @ogilville1 @sduncanhealth @ckellywpg @ASchifty @ValZimmer2 @KuikenAndrew @cbeckj @nuhope2022 @HouseLyndseyRN COVID vaccines are NOT experimental If they were, there wouldn’t be these Phase III Clinical Trials below
@VEGASxNY @NekoleUnknown @LibertyCappy They literally did. Pfizer phase 3 results: https://t.co/kXreUUinGw Moderna phase 3: https://t.co/N2KB9h3a7F J&J phase 3: https://t.co/tIXlx8d5c7
@RachelEph77 @dogwoodcattails @KelownaNow https://t.co/sPeyNOpyhY
@Scotian_CA @dogwoodcattails @KelownaNow Educate yourself. You can't even spell "whore" correctly and think you would be credible about COVID vaccines
@nanaimospots @dogwoodcattails @KelownaNow Educate yourself. https://t.co/sPeyNOpyhY
@RocaSan13 @ChrisKFilms @CityNewsVAN What are your credentials to spew nonsense about vaccines little Ms trumpster?? Oh I know, NONE. Research proves you and your antivaxer ilk wrong. https://t.co/sPeyNOpyhY
@R_DogsRacist @peachiekeehn @TDebeaudra18805 @ChrisKFilms @CityNewsVAN
@Clinteroo1969 @peachiekeehn @TDebeaudra18805 @ChrisKFilms @CityNewsVAN One of dozens of research articles proving you wrong. https://t.co/sPeyNOpyhY
@mitchimio85 @ChrisKFilms @CityNewsVAN Says another armchair immunologist with nothing but a degree in BS from google university and social media. "Hard science" proves the vaccine is safe and effective. This is just one of dozens of research studies. Quit spreading ignorant disinformation. https://t.co/sPeyNOpyhY
@epigeneticallyj @market_memetics @HossmanOfficial @J91U17 @Pouldeau61 @Scary7Dr @nobodyknows1017 @nyob7714 @PickEmLegend @TonyBaduy @Mike61508177700 @saltbeefsandwch @Veeteejay1 @PlatoonOps @charlespinion @mcfunny @JimeeLiberty @jilel76 @SolleyButler @FitnessApple106 @Agent2Dark @dirk_fasshauer @BurgerLab12 @ogilville1 @swords_mr @karleastlondon @sduncanhealth @lavalmxhr @ckellywpg @ASchifty @zee_parody @IckeExposed @ValZimmer2 @KuikenAndrew @cbeckj @nuhope2022 @KinseyKat1 @nickowe49445250 @doom37455413 @RealJonTSmith @TheeLoneGunmen @orwelleye @richykirsh @JKelleyK @villagerssn @NexusSwords @ScooterScience @JordanScottish COVID vaccines are NOT experimental EVERY vaccine completed Phase III Clinical Trials below
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
COVID vaccines are NOT experimental If they were, there wouldn’t be these Phase III Clinical Trials below
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
@stephan19573 @ShaneCook10 @thatsnotmine125 @reignitedemaust EVERY vaccine for COVID is NOT experimental If experimental, they wouldn't have completed Phase III Clinical Trials Pfizer: https://t.co/C81XkLdcHk Moderna: https://t.co/6uEb9jYLjZ J&J: https://t.co/2NVSUgLYpQ https://t.co/hHgaDLBGOC Novavax : https://t.co/6UqfhSljcV
@Catmom32220611 @thechilichick @bocephusfuss @JCDeardeuff @perinejennifer5 @PembrokeMeg @FemmeVoilet @sammy_bivens @flitesurgn @skeeduu @APatienceTryer @BrianRe23316445 @FriendsOfJoe33 @neecbf @clbirds @Pubs1787 @AndrewLazarus4 @MissileFur @jackdoranjr @patechinois1 @LaurieDSouza @RayMosher5 @JSkier69 @Iamclifford @lynne_kenerly @AngryFleas @Cosmos5950 @not2early @Ben__Around @3rdClickCharles @sereneexistence @corbycar @handi817 @HolyAllMighty @KentPerryCorp @KCosta_41 @Billenjoylife @Doubting_1 @KevinMoncla @RogerWallaceTX @hessenjunge76 @CodyFromAcme @SeanGatton @nichpic @VIEWontheRIGHT @Michael47460730 @LeithiserElaine @MamieWhiteesq @hfrank6048 @DecentFiJC and Sadoff J, et al. Safety and efficacy of single- dose Ad26.COV2.S vaccine against COVID- 19. N Engl J Med 2021;384:2187–201.
@JoshuaGaspar @Debunk_the_Funk @rozoveanu All of the clinical trial data is published, you could look it up yourself if you cared to. Here are links to a few: https://t.co/8cWQVAC0Jm https://t.co/A8H2R3P7RU https://t.co/s8LNYQ0dbI https://t.co/pPLMNi3rIu https://t.co/b54GV2uwAU https://t.co/alSDevUjMY
RT @angryhacademic: @msabouri @gadboit Did they? "7 adverse events leading to death occurred in 7 participants in the AZD1222 group,& 9 adv…
@sudokuvariante @ClaudeSteve6 @treponem Celle-ci que le vaccin Johnson et Johnson : https://t.co/qy3i3JazEq
@msabouri @gadboit Did they? "7 adverse events leading to death occurred in 7 participants in the AZD1222 group,& 9 adverse events leading to 7 deaths occurred in the placebo group" "3 deaths occurred in the vaccine group...& 16 in the placebo group" https://t.co/XTaklcWg1t https://t.co/XqwURJgS1X
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
@EEr6919 3/3 ¿Podría usted hacerlo? Le adjunto los link: PFIZER: https://t.co/GRtXepFod4 ASTRAZENECA: https://t.co/lszHErPIN1 MODERNA: https://t.co/upYHh5W9Yd JANSEN: https://t.co/W8CCo1o0Wf No hace falta que estudie las cuatro. Ya me dirá. Saludos.
RT @SARS_CoV_2_2K19: Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZene…
Phase 3 trials Pfizer: https://t.co/nllMjSWhu1 Moderna: https://t.co/k0fw5knEVW J&J: https://t.co/NseCO0llJO AstraZeneca: https://t.co/7uSm3LKsez Novavax: https://t.co/mOrR0EKvpJ
RT @JacksonWheat1: @robbswallace Do you wonder why I posted peer-reviewed scientific papers and you posted a popular news article and a lin…
@robbswallace Do you wonder why I posted peer-reviewed scientific papers and you posted a popular news article and a link that didn't work? Also, oops you're wrong about the vaccine too womp womp https://t.co/wfciWnZtXO
@CitizenXjf60682 @stopvaccinating Johnson and Johnson. https://t.co/8bKP16YslY
@Crissmosp @dharmarin @christianperez https://t.co/uMBmb952qw https://t.co/qXO9Or3uAn https://t.co/zwyuf9Ceof https://t.co/YZ8xy8WY0Z
@Crissmosp @dharmarin @christianperez Pero si la literatura científica está llena de evidencia. No sabes buscar?? https://t.co/oioU7nsYkJ
@EyedRebecca @_aussie17 The evidence: https://t.co/82EHuWAm2r https://t.co/mI3lzWc51Z https://t.co/2FmHmyx7t5 https://t.co/MDCQ3FOjQM
@AlexBerenson 2/2- https://t.co/82EHuWAm2r https://t.co/mI3lzWc51Z https://t.co/2FmHmyx7t5 https://t.co/MDCQ3FOjQM
@LadyRedHawk1111 This study talks about the old fashioned vaccine type (the traditional adenovirus delivery) Modern messenger RNA vaccines do not have as many side effects because there is no live or weakened virus injected- no chance of viral replication. https://t.co/hGGXy3dzFm https://t.co/jsu9Ge6pmc
@ToonVanBeek1 @peter_risselada @Beach_Roy33 Goh, had Johnson nou ook gewoon gepubliceerd? https://t.co/2biAohQEmv Je zult maar zo door de mand vallen met je leugens.
@jeffreyt1981 @gorskon 1:the flu vaccine does work, just not perfectly, and nobody should be claiming it does. if you wish to claim it doesn't work at all provide a citation 2:https://t.co/o3CixKYOoy https://t.co/k8U8onMB59 so these studies are fake? back up your claim with a source
@putasycocas @84DiegoQM @salud71385 @IvanAle_85 @Mentor1Universa @GPlandemiun @amvtw @Luis13104072 @DanielEcidi @Samuel13004969 @No_se_alquila @aliciacgviolin @Jorge06266221 @CarlosVecino4 @jon_tr1ste @Paula13vega @Hondontown @miacat47 @BorregoUnadeca @LeilaYLab @sirkioso @CafeyGrafeno @ashgam666 @jesus_colega_ @Mirambella @SdeSanty @LekLaial @ElRecogelatas @Anorcr1 @AI2BO4 Pero de 2023 no tienes Ningún Estudio, sal de los titulares Mira un estudio
RT @cageygal: @SouthboundTexas @pkcanada1 @VigilantFox @MakisMD Uh, because it’s NOT misinformation. https://t.co/JUE5l6TxnZ
@EyesOpenNoFear @P_McCulloughMD @Walgreens https://t.co/JUE5l6TxnZ
@SouthboundTexas @pkcanada1 @VigilantFox @MakisMD Uh, because it’s NOT misinformation. https://t.co/JUE5l6TxnZ
@MarieClaudeMas7 @JeremyFOUBERT1 @Sabobine_ @mervin13014 @francoisemarte4 https://t.co/WKg0BlLzHG https://t.co/1DJT7cNSxj https://t.co/BRBtNrdnkG C'était pourtant pas super compliqué à trouver, c'est toujours dans l'abstract de chaque étude. https://t.co/j359BScDu4
@VigilantFox Janssen's peer reviewed clinical trial. In the 3 trials mentioned that's well over 100,000 participants. https://t.co/jm3SiQ6iYs
@Retse2022 @veganibalecter 4. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2. Folegatti, PM. 5. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Dagan, N. 6. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine. Sadoff, J.
@msabouri @Standup__Man @CentristAllWay Per your usual technique of pulling it out of where the sun don’t shine. In reality, same standards. https://t.co/2Ofo3TD1kS https://t.co/uXMuk6EePR
@AndrewS80507515 @Jikkyleaks @MonicaGandhi9 Oh, you didn't hear? No wonder you're confused. 1.https://t.co/RSyNxjPyR8 2.https://t.co/K3EWYY4BU0 3.https://t.co/VsOFnXtBu3
@GrahamsAccount1 @GusFlory Pfizer https://t.co/DKFU6j5dCJ Moderna https://t.co/uyVCt2YMsL J and J https://t.co/QNSdlZyO9W correspond in order to images L to R https://t.co/tWsC99j02j
@MMthee0ne @CriticalFailGa2 @EdKrassen Someone didn’t read any of the journals. “19,630 SARS-CoV-2–negative participants who received Ad26.COV2.S and 19,691 who received placebo.” That’s 40k participants right there: https://t.co/lpkV5XaiHu
@FoRRTrES @stkirsch Wrong. The three U.S. Covid-19 vaccines (Pfizer, Moderna and J&J) were all tested against saline placebo in their original clinical trials of over 100,000 people. https://t.co/RSyNxjPyR8 https://t.co/K3EWYY4BU0 https://t.co/VsOFnXtBu3 https://t.co/7QfUlRWOvH
@GregNordo @brotleibe @CDCgov They don't? Please provide evidence. I will do you one better: Pfizer: https://t.co/6l7NRYem5w Moderna: https://t.co/I68P3Agz5N J&J: https://t.co/RaTgNbxSqc AstraZeneca: https://t.co/U5N7WMHhBw
@nnjaann @RVAwonk The Johnson and Johnson vaccine https://t.co/ImrQl1kkvx
@ronaldgizzy @VanEmmerickKris https://t.co/wjZC4U9jLq Hier de resultaten van het onderzoek.
@CorinneReverbel @MahmoudZureik Vous préférez le vaccin Johnson & Johnson? https://t.co/DrC2U6H5Zs
RT @whachex2: @DueDiet Los links: • PFIZER: https://t.co/GRtXepFod4 • ASTRAZENECA: https://t.co/lszHErPIN1 • MODERNA: https://t.co/up…
@mahmudme01 Trial: https://t.co/rEMuAE1ZbB Deaths (though not designed to test efficacy against death): https://t.co/jAzJ0vJL4e
@DueDiet Los links: • PFIZER: https://t.co/GRtXepFod4 • ASTRAZENECA: https://t.co/lszHErPIN1 • MODERNA: https://t.co/upYHh5W9Yd • JANSEN: https://t.co/W8CCo1o0Wf
@anon5standingby @giRlOvErBoArD5 @DHasper @Unity_Coach @LauriHWilliams @WebGuyTV @MarlboroMike2 @_HRH_Victoria_ @delboy00789 @Anti_Dystopian @JustAMan37 @cgauthier592 @Millska21 @RBarker0341 @kathy_atkin @CoryRove @TakethatCt @magicnumber41 @ADevotedYogi @BlaylockMooky @Tdillon06 @umfpt @merlin_saint @Caramel_HoneyB @vandahl7 @AltavozMagalong @kiwi_kent @Michael94173566 @OOOimUrAngel @DebateOnFacts @Ravi1236541 @arduatendit @375NorseLegend @BreakingNewsFi2 @LeenerTep @MikeinHalifax @trevormarr1 @Service_Proof @GeezercitizenX @jmcstow @queenbee0568 @Reneep43 @1D10Two @AveryJames33 @EarthOne_13 @Mummymobbsback1 @teamphil @SteveBuckeye23 @TruthPyRate @mjoyce1950 Oh look, another one. Man, your research skill suck https://t.co/tmfgDJXkeR
@CurlsPrissy @9illeh @DailyLoud Studies keep showing that it does. https://t.co/BG4rOR6H5s; https://t.co/EEChTe45m2; https://t.co/bPpBmUrSbz
@ChatSecouriste @Tarawinterr Et sinon, si vous ne voulez pas de cette meta, l'essai du Janssen était significatif à lui seul, avec une réduction de la mortalité toutes causes de 80% Et c'est publié dans le NEJM. 2/n https://t.co/k2LOVSd7rO
@rhok0 @JeffD38 @VigilantFox 1Moderna COVID-19 vaccine clinical trial: https://t.co/Yh4ttj63n2 2Johnson & Johnson COVID-19 vaccine clinical trial: https://t.co/zSatRHVdp8 3AstraZeneca COVID-19 vaccine clinical trial: https://t.co/M5RDQzlLPr
12/21 Se você ainda não está satisfeito, também pode ir conferir os artigos da AstraZeneca (inclusive dos estudos que incluíram os brasileiros) https://t.co/s2q43ngXMB https://t.co/UoumecCnWW Ou da Janssen tbm https://t.co/eTaHXl4ViL E da CovLP https://t.co/TsPtqpCe7A https://t.co/PXz4ghmCVJ
@mellefluous @juneslater17 Sadoff, J., Gray, G., Vandebosch, A., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine, 384(23), 2187-2201. https://t.co/czNlhRdim9
https://t.co/mub7NLbQc6
@LelenaPeacock @jvgraz @RealSteveCox @twittposter @lmcsomewhere @RogerAramayo2 @jimmy_dore Here's the RCT for Johnson and Johnson. https://t.co/pPLMNi3Zy2
@Manosphere101 @MarioNawfal https://t.co/dtQ2ZRVU8D
@YellowDoc2 @YouplaFr @DeBunKerEtoiles https://t.co/k2LOVSd7rO
@Staninsd @QuranDon @samanthamarika1 You moved the goalpost btw: https://t.co/HgoX5mStXF https://t.co/QCKLzpp6bA
@Seb_81_ @jonathanstea @BrescianiRod @ThinkingPowers @CaulfieldTim @CIRCE_team @DrAndyNo @TheSGEM I hesitate to even respond, but that’s a false anti-vaxx talking point. Moderna Phase 3: https://t.co/GaKUG2r1im. Pfizer Phase 3: https://t.co/1Gy7CUZeMb. J&J Phase 3: https://t.co/eXqPxxEmAj
RT @ezikusia: @CorrNotCausa @Farmaenfurecida @Ari_Arifu2 Bueno, veamos cuanto tardas en mover la portería. Seguridad y eficacia de una va…
@CorrNotCausa @Farmaenfurecida @Ari_Arifu2 Bueno, veamos cuanto tardas en mover la portería. Seguridad y eficacia de una vacuna de vector viral. No son modelos, ni casos anecdóticos, ni opiniones. Es un ensayo clínico aleatorizado y doble ciego (con su correspondiente grupo control). https://t.co/kLKQP63Sjf
@Ussignur_ @longagnani @MatteoRedaelli8 @il_pat @TIRODELTAPPETO @WendellGee1985 @Carlo314159 https://t.co/MnjElU7IS9 https://t.co/ryhZXvFIdH https://t.co/kRmoPAZkA9 https://t.co/0nsk6NSsWd non so di quali dati parli. Tutti gli studi sono constanti nel definirne l'efficacia, cosi come i report di salute pubblica
@PierreProt1 @GabinJean3 @picard_jl @Tommy_Addams @SinedWarrior Ok. à ma connaissance le seul RCT peer-reviewé à avoir été significatif sur la mortalité est celui de Janssen, avec 3 morts vaccinés vs 16 non vaccinés. Et c'est paru dans le NEJM. OR mortalité toutes causes de 0.19 https://t.co/k2LOVSdFhm https://t.co/umVqRPmNnB
@EwanMacKenna @PGriffinFC @keegolaughs_irl You don't like actual evidence Ewan but here I have posted the initial results from the J&J clinical trial. So what are you on about again??? https://t.co/kFGM4ULqbe https://t.co/YDxhkiofU0
@ecozdence @dr_phototherapy @stabilyorgun @tuncsoyer AstraZeneca https://t.co/Pq3NtNfRey Johnson & Johnson https://t.co/N2rCXlYgwE
@ecozdence @dr_phototherapy @stabilyorgun @tuncsoyer Biontech faz 3 https://t.co/AlTD4Ka8gQ Sinovac https://t.co/1tHoESBxXY Moderna https://t.co/PJBfZxGsiC AstraZeneca https://t.co/Pq3NtNfRey Johnson & Johnson https://t.co/N2rCXlYgwE
@Kevin_McKernan https://t.co/WdY8yAeDxC. https://t.co/S42CgzPnXJ https://t.co/KpUye1BZhO https://t.co/U0hVroDhht. https://t.co/oKlmwTT6xA
@ru_dalton @orange_twitt @NikiHandy @MelissaKXLY4 @jimmywhart @joshtpm https://t.co/Xa9xtZU8dN 1/3
@felice_nano @ilmora61 @GiusePat @LaBombetta76 https://t.co/q7ERYLvbj2
@BurnerZte @thecrow124 @Ringo3911 @JeffPassan Start here…https://t.co/zVYC6vtcgI
@ShrederHank @JoseMar96968638 @quendagrace @BOROWSKIMIKE @THEVENONPierri1 https://t.co/y5W9nUE45l https://t.co/rZ1aE1KGeN https://t.co/Vag0flq0Si https://t.co/BLbnN4I12t https://t.co/UwSjzL5MET https://t.co/GV5uTU8Cbi
@NCopertnicus @Marcin_Soc https://t.co/KKNvs2FDjo Albo ten.
@rosewood2019 @decoder_l @AnarchroniqueS @jenyhart2 @GuisonJerome @DocAmine_ @mauriceIarm2022
@rosewood2019 @AnarchroniqueS @jenyhart2 @GuisonJerome @DocAmine_ @mauriceIarm2022 @decoder_l Sans argument? Vraiment? Vous avez cité 000 études pour rappel Un peu de lecture si vous en avez les capacités : https://t.co/luJXYLwsP2 https://t.co/2d1jeV3ThP https://t.co/hMhD3kcd5t https://t.co/eiGrcOSDKr https://t.co/UYQ86Kn3oB
@jenyhart2 @decoder_l @rosewood2019 @AnarchroniqueS @GuisonJerome @DocAmine_ @mauriceIarm2022 Très bien. Les maths permettent aussi de conclure que le vaccin est efficace. Lisez et vous le verrez vous-même : https://t.co/eiGrcOSDKr
The focus for this paper should be on the RCT with the largest differences in deaths which is J&J. Once again this article used an old study instead of the updated one: J&J used https://t.co/xK8MhQqI9p but update: https://t.co/KpUye1BZhO
@skrzypiec_jacek @murray_nyc @DjokerNole "Experiment" really? 1/n You just straight-up lied. Here are the phase 3 results of Pfizer/BioNTech: https://t.co/W7GtWMWqjW Here it is for Moderna: https://t.co/YrP2grO1gb Here it is for J&J: https://t.co/RaTgNbfJc4 Here it is for AstraZeneca: https://t.co/U5N7WMp8no
@SapperDeKriek @HaHaGentherapie En de volgende voor je feitenresistente nietsnut die je bent https://t.co/DFRw2zTmVr Johnson & Johnson
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/xmOLcWycQq
@Ninnis_tankar @IzabellaMBA @doffsingen Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.
@Mehrnoosh ... من لینک مطالعه بالینی فاز ۳ هر چهار واکسن معتبر دنیا رو میذارم اینجا در هیچکدوم seroconversion و مقدار آنتیبادی از پیامدها یا endpointهای مطالعه نیستن https://t.co/rXrVjgKNti https://t.co/CBIYSsQXEK https://t.co/2tHmubvhbr https://t.co/2w5IIJPeBD
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM #jnjvaccine https://t.co/y5V1GiVd6l
@Maxipsycho And here's the original randomized control rial with the control group which ALSO showed a large reduction in hospitalizations: https://t.co/mZE5wkhSgv
@Maxipsycho Also, they literally cite the vaccine trials which also showed a huge reduction in hospitalization: https://t.co/mZE5wkhSgv "Vaccine efficacy against hospitalization among vaccine recipients 60 years of age or older with coexisting conditions was 82%..."
ジョンジョンもワクチンやってたんだね。 しかもシングルショットだと? 今後の動きに少し期待しておきましょうかね。 https://t.co/lTpCMjbcuc
@gloxxie @FutureMemori @Timcast https://t.co/U7srVGIe6s https://t.co/EWHuZVoaf4 https://t.co/tAkJDT2Zir https://t.co/jHyYWsmsj0 https://t.co/pSsMhHbW7c
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/FBBF4VPCuH
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM - https://t.co/oj1z87YYw2 https://t.co/3YD0QIg1r6
RT @smadixit: Clinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vacc…
RT @smadixit: Clinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vacc…
RT @smadixit: Clinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vacc…
RT @smadixit: Clinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vacc…
Clinical trial results of single dose #johnsonandjohnson vaccine due to arrive into #nepal this Monday. Conclusion: safe vaccine, works well against hospitalization and death ! 'Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | https://t.co/N9TWQWOUP6
RT @buckleyswartz: The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d Sadoff J, Gray G, Va…
The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021. [Epub ahead of print.] https://t.co/uMrZdAEnL2
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/lbrtY7gYkD
Full J&J study published last week in @NEJM -- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/TICYh7yqkM https://t.co/XHgPHgxhiu
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/laErKTkUmK
@kutzfek Pero no se enfade. Si yo le pondría artículos como este: https://t.co/3y9OYxmWBO Pero sé que no lo va a leer porque seguramente no lo entendería. Si le molesta, cierre la puerta.
日本語abstract Covid-19 に対する Ad26.COV2.S ワクチンの単回接種の安全性と有効性 Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 June 10, 2021 Vol. 384 No. 23 https://t.co/lu5GvNDZdC
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/R5l9jsPp8R
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LtKYg3gQnv
冠状病毒
RT @melmarkoski: A vacina de adenovírus Janssen (J&J) mostrou 64% de proteção contra doenças moderadas a graves na África do Sul e 66% de p…
A vacina de adenovírus Janssen (J&J) mostrou 64% de proteção contra doenças moderadas a graves na África do Sul e 66% de proteção contra doenças moderadas a graves nos EUA (principalmente a variante Wuhan-1 com D614G). https://t.co/uyfYBZzVom
RT @RegaCarlos: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/eq4C1fgOXt
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/eq4C1fgOXt
@MarkPlackett1 @viget99 @DxImmunity Mark do you happen to know if the J&J trial followed the same protocol of only reporting thrombocytopenia graded 3 or above? I've searched all the appendices on NEJM and the trial protocol and don't see any mention of thrombocytopenia at all https://t.co/WmuKroxQ1u
Summary: This first peer-reviewed report of the phase 3 clinical trial results for the Johnson & Johnson/Janssen Pharmaceuticals Ad26.COV2.S COVID-19 vaccine shows efficacy against symptomatic #COVID19 disease and #SARSCoV2 infection. https://t.co/0Hz0eS16PY
In @nejm, Sadoff et al present data from an ongoing vaccine trial in South Africa, the U.S., & Latin America, including 40,000 participants (half randomized to placebo) from September 2020-January 2021. They estimated efficacy 14 and 28 days post-vaccine. https://t.co/KBKHBXftux https://t.co/zjIxv2aCZg
RT @Globalbiosec: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/Qv1vb0yU5s
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/4x57w3uc8q
@angie_rasmussen On what do you base the protection for 8 out of 9 cases based? Based on the phase 3 study results, vaccine efficacy is more like 6 out of 9. https://t.co/6PbstIDgoZ https://t.co/dtSb09EUGB
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/iHK6DFO0kE
RT @JuanjoArm: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. https://t.co/rVEN9Qt2E4
RT @PedroNunez: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/pSLuNfid6q
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/pSLuNfid6q
RT @Fiatopichan: Incidence ของโรคส่งผลกับ efficacy ของวัคซีนไหม ลองอ่าน Ref 37-39 ดู https://t.co/lqbUmxf1Yj https://t.co/R1fBWfpMNx
Incidence ของโรคส่งผลกับ efficacy ของวัคซีนไหม ลองอ่าน Ref 37-39 ดู https://t.co/lqbUmxf1Yj https://t.co/R1fBWfpMNx
Estudio multicéntrico y controlado sobre la vacuna J&J demostró un 66.2% de eficacia en prevenir los síntomas de Covid y un 66.9% en prevenir Covid moderado a grave. 11 y 4 casos de tromboembolia ocurrieron en los grupos vacuna y placebo, respectivamente. https://t.co/AX4dltZZpk
@NoBrakesForMe @BrotherJev @AboutPediatrics @PeterHotez It isn't in "trial". Phase 3 results have been completed and published. Pfizer made the shedding claim? https://t.co/ptOXtc2RHt https://t.co/ieQmd2RnvJ https://t.co/l3C977VVJA
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LAqhHYAaxE
RT @4defensa: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/bIJg7dw36y
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/Qv1vb0yU5s
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/A1Fe7Digvb
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/bIJg7dw36y
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/xIiGcoPRC7
いえーい✌️ウイルスバスターがインストールされました Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/dNDmK3S7LB
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/1k0fbxpO3E https://t.co/Fd4btYxUQl
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/V4MyvjotZU
RT @DocFlo4: @ScrootyB @LViehler Natürlich: https://t.co/R3NYiBbP2Z
Janssen, jedno dávková, vektorová, už jsem o ní psal dříve. Cca 2x 19600 dobrovolníků. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/wJsrDTNJ36 https://t.co/GNjLywUrNJ - via Researcher (@ResearcherApp)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/lN5YjCW61q
@ScrootyB @LViehler Natürlich: https://t.co/R3NYiBbP2Z
RT @bar1star: J&Jのウイルスベクターワクチン 19630人VS19691人のRCT 1回接種 14日以上で 中等症〜重症 66.9%減 重症〜重篤 76.7%減 28日以上で 中等症〜重症 66.1%減 重症〜重篤 85.4%減 https://t.co/DY…
RT @bar1star: J&Jのウイルスベクターワクチン 19630人VS19691人のRCT 1回接種 14日以上で 中等症〜重症 66.9%減 重症〜重篤 76.7%減 28日以上で 中等症〜重症 66.1%減 重症〜重篤 85.4%減 https://t.co/DY…
RT @bar1star: J&Jのウイルスベクターワクチン 19630人VS19691人のRCT 1回接種 14日以上で 中等症〜重症 66.9%減 重症〜重篤 76.7%減 28日以上で 中等症〜重症 66.1%減 重症〜重篤 85.4%減 https://t.co/DY…
J&Jのウイルスベクターワクチン 19630人VS19691人のRCT 1回接種 14日以上で 中等症〜重症 66.9%減 重症〜重篤 76.7%減 28日以上で 中等症〜重症 66.1%減 重症〜重篤 85.4%減 https://t.co/DYQ0TVF0EA
Trending on PubMed: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. https://t.co/HpsUOl3TvA
RT @jeparletoutseul: Ah, j'avais loupé cette info de la semaine dernière : Janssen a ENFIN publié les résultats de son étude (ENSEMBLE). Un…
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @VoiceOfFranky: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LCWcXHTokr
RT @VoiceOfFranky: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LCWcXHTokr
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LCWcXHTokr
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
RT @minesoh: J&J のワクチンの効果と安全性報告論文
J&J のワクチンの効果と安全性報告論文
Ah, j'avais loupé cette info de la semaine dernière : Janssen a ENFIN publié les résultats de son étude (ENSEMBLE). Un mois et demi après son autorisation, et tout juste à temps pour ses premières livraisons concrètes. Avec une discussion du variant sud-af https://t.co/nPwSB2JoMa
RT @carpe_diem0820: J&Jワクチンの第3相試験最終結果 単回接種後14日以降の中等度以上のCOVID-19予防効果は67% 静脈血栓塞栓症は11対3例でワクチン群により多い ワクチン接種者1例に脳出血を伴う横静脈洞血栓症あり Safety and Effi…
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/lUK6FjrY21
J&J clinical trial results are out @NEJM https://t.co/XXJJMs9dv3
Seguridad y eficacia de la vacuna de dosis única Ad26.COV2.S contra Covid-19 | NEJM https://t.co/JTo7vG48UB
RT @Guia_ABE: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/MhVTUgvV3G
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/4QUANPJaaz
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/zKsBcTJIDX
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/8PwHoPJA9w
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/MhVTUgvV3G
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/OuZpznIyti
RT @infdisease_news: Published in @NEJM: A single dose of Ad26.COV2.S protected against symptomatic #COVID-19 and asymptomatic #SARS-CoV-2…
Published in @NEJM: A single dose of Ad26.COV2.S protected against symptomatic #COVID-19 and asymptomatic #SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death. https://t.co/Cc2K4hhDko https://t.co/O7xPBVnuYm
Excelente noticia!! The J&J vaccine Phase 3 trial is published @NEJM today At post >14 days 67% efficacy; >28 days 75% (85% vs severe/critical) and strong efficacy vs B.351 (South Africa) variant; very good safety profile https://t.co/vP2HYV6AJY https://t.co/sEBZXgzYVg
J&J COVID-19 vaccine study-Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/L0pI69UW8n
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/b0gY9ZuwfK
Trend top+1: Sadoff J, ..., Ensemble Study Group (N Engl J Med) __Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19__ https://t.co/CmRpO23Hq9
RT @pedrocintra52: Para ter boas notícias na sexta, vamos ver os resultados de fase 3 da 2ª formulação de vacina da Janssen! Um estudo muit…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @FERRJOAN: Esta vacuna Janssen me pondrán mañana.
Esta vacuna Janssen me pondrán mañana.
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
Para ter boas notícias na sexta, vamos ver os resultados de fase 3 da 2ª formulação de vacina da Janssen! Um estudo muito bom incluindo participantes no Brasil e na África do Sul, onde duas variantes de preocupação circulam + https://t.co/idM61s1UfF
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @emorychoa_CCIV: Proud to serve as a site for the J&J ENSEMBLE study under the leadership of Evan Anderson: 66% efficacy against sympto…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1️⃣ Eficacia del 66% frente a in…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
Trend new: Sadoff J, ..., Ensemble Study Group (N Engl J Med) __Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19__ https://t.co/CmRpO23Hq9
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @ALEX_MISCHIE: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/w5af88xGVz
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @gorka_orive: Resultados del ensayo clínico (40.000 voluntarios) con dosis única de Johnson & Johnson: 1. Eficacia del 66% frente a la…
RT @iic_a: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/W8mcqPlYfK
Ótimos resultados de mais uma formulação de vacina DOSE ÚNICA da Janssen. Amanhã faço uma thread com os detalhes. Eles calcularam a eficácia para várias escalas diferentes de severidade e incluíram a variante B.1.351. Quem quiser ler o artigo logo
Finally, J & J paper is out in @NEJM " Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19" | NEJM https://t.co/MW7D7YLU9e
New article: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/mYtpUUvDwz #coronavirus #COVID19 #2019ncov https://t.co/mEOTa839Hl
Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19 https://t.co/J1gg4Gr9N8 vía @docguide
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/LVwrsrFXlL
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 https://t.co/BJ55Nma2wx #covid19ase
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/xTKqc8mTTc Great results!
RT @ProfJLundgren: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | a.k.a. as the “Janssen” or “Johnson&Johnson”va…
RT @ProfJLundgren: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | a.k.a. as the “Janssen” or “Johnson&Johnson”va…
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/15BgbOWnOS
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/8gtfDaaDFI
Phase 3 results from the J&J vaccine clinical trial out now. #COVID19 #SARSCoV2 #vaccinated #vaccines Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/QuWPIFYSpI
RT @UnmeshDr: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 | NEJM https://t.co/Y14omZ9UxU @naveenthacker @vipin…
RT @aslan2626: J&JワクチンのPhase3がNEJMに掲載された。 接種2/4週後以降で発症66.9%/66.5%減、入院93.1%/100%減、重症化76.7%/85.4%減。 南ア・ブラジルでも効果はほぼ同等。 https://t.co/VQnbYXqRFM…
J&JワクチンのPhase3がNEJMに掲載された。 接種2/4週後以降で発症66.9%/66.5%減、入院93.1%/100%減、重症化76.7%/85.4%減。 南ア・ブラジルでも効果はほぼ同等。 https://t.co/VQnbYXqRFM https://t.co/fmYsOWrOJ7